| 000 | 01823 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515072139.0 | ||
| 264 | 0 | _c20070731 | |
| 008 | 200707s 0 0 eng d | ||
| 022 | _a0041-1337 | ||
| 024 | 7 |
_a10.1097/01.tp.0000263344.53000.a1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aThomas, Philip G | |
| 245 | 0 | 0 |
_aAlemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. _h[electronic resource] |
| 260 |
_bTransplantation _cJun 2007 |
||
| 300 |
_a1509-12 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAlemtuzumab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntibodies, Neoplasm _xadverse effects |
| 650 | 0 | 4 | _aAntilymphocyte Serum |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGraft Rejection _xepidemiology |
| 650 | 0 | 4 | _aGraft Survival |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 |
_aKidney Transplantation _xmortality |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMycophenolic Acid _xtherapeutic use |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSteroids _xtherapeutic use |
| 650 | 0 | 4 |
_aTacrolimus _xtherapeutic use |
| 650 | 0 | 4 |
_aTransplantation Tolerance _xdrug effects |
| 700 | 1 | _aWoodside, Kenneth J | |
| 700 | 1 | _aLappin, Jacqueline A | |
| 700 | 1 | _aVaidya, Smita | |
| 700 | 1 | _aRajaraman, Srinivasan | |
| 700 | 1 | _aGugliuzza, Kristene K | |
| 773 | 0 |
_tTransplantation _gvol. 83 _gno. 11 _gp. 1509-12 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/01.tp.0000263344.53000.a1 _zAvailable from publisher's website |
| 999 |
_c17103615 _d17103615 |
||